ESAB Corporation delivered a strong second quarter in 2025, with sales reaching $716 million. The company achieved a record core adjusted EBITDA margin of 20.4% and reported diluted EPS of $1.12, with core adjusted EPS at $1.36. Strategic acquisitions in medical gas control and welding equipment further strengthened its market position, leading to an upward revision of its full-year 2025 guidance.
ESAB reported second quarter sales of $716 million, a 1% increase on a reported basis compared to the prior year.
The company achieved a record core adjusted EBITDA margin of 20.4%, reflecting consistent performance and resilience.
Diluted earnings per share (EPS) from continuing operations were $1.12, and core adjusted diluted EPS was $1.36.
ESAB completed two Gas Control acquisitions (DeltaP and Aktiv) and signed one Fab Tech acquisition (EWM), advancing its compounder strategy.
ESAB Corporation has raised its full-year 2025 outlook, anticipating higher total core sales growth, increased core adjusted EBITDA, and improved core adjusted EPS.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance